SG11202102882YA - Antigen-binding molecule comprising altered antibody variable region - Google Patents
Antigen-binding molecule comprising altered antibody variable regionInfo
- Publication number
- SG11202102882YA SG11202102882YA SG11202102882YA SG11202102882YA SG11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- variable region
- binding molecule
- antibody variable
- altered antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018185120 | 2018-09-28 | ||
| PCT/JP2019/038087 WO2020067399A1 (en) | 2018-09-28 | 2019-09-27 | Antigen-binding molecule comprising altered antibody variable region |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102882YA true SG11202102882YA (en) | 2021-04-29 |
Family
ID=69950667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102882YA SG11202102882YA (en) | 2018-09-28 | 2019-09-27 | Antigen-binding molecule comprising altered antibody variable region |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220112296A1 (ko) |
| EP (1) | EP3856789A4 (ko) |
| JP (1) | JP2022501325A (ko) |
| KR (1) | KR20210068061A (ko) |
| CN (1) | CN113260634A (ko) |
| AU (1) | AU2019347408A1 (ko) |
| BR (1) | BR112021005472A2 (ko) |
| CA (1) | CA3113594A1 (ko) |
| MX (1) | MX2021003609A (ko) |
| SG (1) | SG11202102882YA (ko) |
| WO (1) | WO2020067399A1 (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI652279B (zh) | 2013-11-11 | 2019-03-01 | 中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
| WO2016076345A1 (ja) | 2014-11-11 | 2016-05-19 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
| WO2019111871A1 (en) | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
| JP7085666B2 (ja) | 2020-03-31 | 2022-06-16 | 中外製薬株式会社 | Ｄｌｌ３標的多重特異性抗原結合分子およびその使用 |
| BR112022017526A2 (pt) * | 2020-03-31 | 2022-10-18 | Chugai Pharmaceutical Co Ltd | Método para produzir moléculas de ligação de antígeno multiespecíficas |
| TW202204410A (zh) * | 2020-03-31 | 2022-02-01 | 日商中外製藥股份有限公司 | 免疫活化多特異性抗原結合分子及其用途 |
| CR20220540A (es) * | 2020-03-31 | 2022-12-07 | Chugai Pharmaceutical Co Ltd | Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos |
| WO2023053272A1 (en) * | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| JP7470760B2 (ja) * | 2021-09-29 | 2024-04-18 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| JPWO2023053282A1 (ko) * | 2021-09-29 | 2023-04-06 | ||
| US20230340461A1 (en) * | 2022-02-14 | 2023-10-26 | Twist Bioscience Corporation | Combinatorial dna assembly for multispecific antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| SG10201407908VA (en) * | 2008-12-19 | 2015-01-29 | Macrogenics Inc | Covalent diabodies and uses thereof |
| WO2012064792A2 (en) * | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| TWI652279B (zh) * | 2013-11-11 | 2019-03-01 | 中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
| SG11201606850QA (en) * | 2014-03-12 | 2016-09-29 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| WO2015146438A1 (ja) * | 2014-03-26 | 2015-10-01 | 国立大学法人東北大学 | ヒト上皮増殖因子受容体を標的とした二重特異性抗体 |
| TWI726842B (zh) | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
| EP3305322A4 (en) * | 2015-06-05 | 2018-12-26 | Chugai Seiyaku Kabushiki Kaisha | Combined use of immune activators |
| WO2019111871A1 (en) * | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
| CN113286824A (zh) * | 2018-08-03 | 2021-08-20 | 中外制药株式会社 | 包含两个彼此连接的抗原结合结构域的抗原结合分子 |
-
2019
- 2019-09-27 WO PCT/JP2019/038087 patent/WO2020067399A1/en unknown
- 2019-09-27 AU AU2019347408A patent/AU2019347408A1/en active Pending
- 2019-09-27 CN CN201980078208.6A patent/CN113260634A/zh active Pending
- 2019-09-27 MX MX2021003609A patent/MX2021003609A/es unknown
- 2019-09-27 BR BR112021005472-3A patent/BR112021005472A2/pt unknown
- 2019-09-27 JP JP2021512586A patent/JP2022501325A/ja active Pending
- 2019-09-27 SG SG11202102882YA patent/SG11202102882YA/en unknown
- 2019-09-27 CA CA3113594A patent/CA3113594A1/en active Pending
- 2019-09-27 US US17/280,239 patent/US20220112296A1/en active Pending
- 2019-09-27 EP EP19866387.4A patent/EP3856789A4/en active Pending
- 2019-09-27 KR KR1020217011976A patent/KR20210068061A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| EP3856789A4 (en) | 2022-08-17 |
| CA3113594A1 (en) | 2020-04-02 |
| WO2020067399A1 (en) | 2020-04-02 |
| MX2021003609A (es) | 2021-05-28 |
| AU2019347408A1 (en) | 2021-04-15 |
| CN113260634A (zh) | 2021-08-13 |
| US20220112296A1 (en) | 2022-04-14 |
| BR112021005472A2 (pt) | 2021-06-15 |
| JP2022501325A (ja) | 2022-01-06 |
| EP3856789A1 (en) | 2021-08-04 |
| KR20210068061A (ko) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202102882YA (en) | Antigen-binding molecule comprising altered antibody variable region | |
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL279321A (en) | Anti-SIRPalpha antibody | |
| SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
| IL283812B (en) | Humanized antibody against human pd–1 | |
| IL263936A (en) | Humanized monoclonal antibodies targeting hptp-beta)ve-ptp) | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| SG11202009361PA (en) | Her3 antigen-binding molecules | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| ZA202205226B (en) | Ri-labeled humanized antibody | |
| EP3567053A4 (en) | MONOCLONAL ANTI-CLAUDIN-2 ANTIBODY | |
| EP3590964A4 (en) | IMPROVED MONOCLONAL ANTI-VEGFR-2 ANTIBODY | |
| ZA202004908B (en) | Bispecific antibody | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| GB201811403D0 (en) | Antibody molecules | |
| IL279355A (en) | Antigen binding protein against STEAP1 | |
| IL279823A (en) | Antibodies cultured against PSMA | |
| GB201817172D0 (en) | Antibody | |
| IL292799A (en) | Antibodies against siglec-9 | |
| EP3877420A4 (en) | HER2-S310F-SPECIFIC ANTIGEN BINDING MOLECULE | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| EP3753956A4 (en) | ANTIGEN BINDING MOLECULE AND COMBINATION | |
| EP3656791A4 (en) | HUMAN ANTI-CCR1 MONOCLONAL ANTIBODY | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody |